Skip to main content
OverweightWeight lossWeight managementDrugPhase 2

What this study is

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.

What's being tested

  • Macupatide

    Intervention · DRUG

  • Eloralintide

    Intervention · DRUG

  • Placebo

    Intervention · DRUG

All interventions

Administered SC

Study details

Official title
A Phase 2b, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes
Sponsor
Eli Lilly and Company
Conditions
Overweight · Obesity
Enrolling
400 people
Starts
2026-05-15
Est. completion
2028-02
Design
Double-blind, randomized, parallel groups, Phase 2
Record
View on ClinicalTrials.gov ↗